We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
| Symbol | Name | Price (Intraday) | Change | % Change | Volume | Avg Vol (3 month) | Market Cap | PE Ratio (TTM) | 52 Week Range |
|---|---|---|---|---|---|---|---|---|---|
| SNWV | SANUWAVE Health, Inc. | 4,423 | 4.07 | ||||||
| SNWVD | SANUWAVE Health, Inc. | 4,423 | 3.66 | ||||||
| CATX | Perspective Therapeutics, Inc. | 861,406 | N/A | ||||||
| SRTS | Sensus Healthcare, Inc. | 157,437 | 15.61 | ||||||
| DCTH | Delcath Systems, Inc. | 315,793 | N/A | ||||||
| BVS | Bioventus Inc. | 574,910 | N/A | ||||||
| PRCT | PROCEPT BioRobotics Corporation | 845,789 | N/A | ||||||
| ELMD | Electromed, Inc. | 59,332 | 40.09 | ||||||
| AXGN | Axogen, Inc. | 455,001 | N/A | ||||||
| ECOR | electroCore, Inc. | 37,600 | N/A | ||||||
| CLPT | ClearPoint Neuro, Inc. | 206,504 | N/A | ||||||
| ESTA | Establishment Labs Holdings Inc. | 385,342 | N/A | ||||||
| GKOS | Glaukos Corporation | 510,976 | N/A | ||||||
| LNSR | LENSAR, Inc. | 30,007 | N/A | ||||||
| INGN | Inogen, Inc. | 200,335 | N/A | ||||||
| UFPT | UFP Technologies, Inc. | 56,526 | 41.65 | ||||||
| AORT | Artivion, Inc. | 220,507 | N/A | ||||||
| BSX | Boston Scientific Corporation | 5.53M | 69.44 | ||||||
| AHCO | AdaptHealth Corp. | 1.078M | N/A | ||||||
| GMED | Globus Medical, Inc. | 786,343 | 367.70 | ||||||
| SERA | Sera Prognostics, Inc. | 93,731 | N/A | ||||||
| RXST | RxSight, Inc. | 453,840 | N/A | ||||||
| ITGR | Integer Holdings Corporation | 265,650 | 37.31 | ||||||
| NSYS | Nortech Systems Incorporated | 6,446 | 5.23 | ||||||
| MASI | Masimo Corporation | 710,315 | 97.97 |
- ACCESSWIRE
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and ...
ZacksOMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised
Omnicell continues its trend of impressive results in the third quarter of 2024.
ZacksLooking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice
Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.
ZacksThe Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.
ZacksEnvista Stock Climbs on Q3 Earnings and Revenue Beat, Margins Crash
NVST delivers better-than-expected top and bottom-line performance in the third quarter of 2024.
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks
Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
ZacksPenumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
ZacksCONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
ZacksMMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.
